~~In one aspect, the disclosure relates to use of an antibody binding to human CSF-1R in the manufacture of a medicament for the treatment of cancer, wherein the antibody is to be administered in combination with a bispecific ANG-2-VEGF antibody~~

In ~~another~~ one aspect, the disclosure relates to use of an antibody binding to human CSF-1R in the manufacture of a medicament for the treatment of cancer, wherein the anti-CSF-1R antibody is to be administered in combination with an agonistic CD40 antibody.

Description of the Figures

Figure 1 Growth inhibition of BeWo tumor cells in 3D culture under treatment with different anti-CSF-1R monoclonal antibodies at a concentration of 10µg/ml.
X axis: viability normalized mean relative light units (RLU) corresponding to the ATP-content of the cells (CellTiterGlo assay).
Y axis: tested probes: Minimal Medium (0.5% FBS), mouse IgG1 (mIgG1, 10µg/ml), mouse IgG2a (mIgG2a 10µg/ml), CSF-1 only, Mab 2F11, Mab 2E10, Mab2H7, Mab1G10 and SC 2-4A5.
Highest inhibition of CSF-1 induced growth was observed with the anti-CSF-1R antibodies according to the invention.

Patent Claims

~~1. Use of an antibody binding to human CSF-1R in the manufacture of a medicament for the treatment of cancer, wherein the antibody is to be administered in combination with a bispecific ANG-2-VEGF antibody.~~

21. Use of an antibody binding to human CSF-1R in the manufacture of a medicament for the treatment of cancer, wherein the anti-CSF-1R antibody is to be administered in combination with an agonistic CD40 antibody.

32. The use according to claim 21,
i) wherein the anti-CSF-1R antibody comprises (a) a heavy chain variable domain amino acid sequence of SEQ ID NO:39 and (b) a light chain variable domain amino acid sequence of SEQ ID NO:40; and
ii) wherein the agonistic CD40 antibody comprises (a) a heavy chain variable domain amino acid sequence of SEQ ID NO: 88 and (b) a light chain variable domain amino acid sequence of SEQ ID NO: 89.

43. The use according to claim 21, wherein the anti-CSF-1R antibody comprises (a) a heavy chain variable domain amino acid sequence of SEQ ID NO:39 and (b) a light chain variable domain amino acid sequence of SEQ ID NO:40; and
wherein the agonistic CD40 antibody is dacetuzumab.

54. The use according to claim 21,
i) wherein the anti-CSF-1R antibody comprises (a) a heavy chain variable domain amino acid sequence of SEQ ID NO:39 and (b) a light chain variable domain amino acid sequence of SEQ ID NO:40; and
ii) wherein the agonistic CD40 antibody comprises (a) a heavy chain variable domain amino acid sequence of SEQ ID NO: 90 and (b) a light chain variable domain amino acid sequence of SEQ ID NO: 91.